newsfilter
← Latest News
Business Wire·

Organon Completes Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

This transaction strengthens Organon’s contraception portfolio and expands long-acting reversible options for women Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and